Lenvatinib Suppresses Angiogenesis through the Inhibition of both the VEGFR and FGFR Signaling Pathways
Open Access
- 2 July 2016
- journal article
- Published by Peertechz Publications Private Limited in Global Journal of Cancer Therapy
- Vol. 2 (1), 019-025
- https://doi.org/10.17352/gjct.000009
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Basic and Therapeutic Aspects of AngiogenesisCell, 2011
- FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in boneJournal of Bone and Mineral Research, 2011
- VEGF and angiopoietin signaling in tumor angiogenesis and metastasisTrends in Molecular Medicine, 2011
- Biomarkers of angiogenesis and their role in the development of VEGF inhibitorsBritish Journal of Cancer, 2009
- The FGF system has a key role in regulating vascular integrityJCI Insight, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacyProceedings of the National Academy of Sciences of the United States of America, 2007
- VEGF receptor signalling ? in control of vascular functionNature Reviews Molecular Cell Biology, 2006
- Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell, 2005
- Ligand-induced Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) Heterodimerization with VEGFR-2 in Primary Lymphatic Endothelial Cells Regulates Tyrosine Phosphorylation SitesOnline Journal of Public Health Informatics, 2003